Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Burger

Showing results (821-830 of 1,123) with videos related to

Pageof 113
Sort By:
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 17, 2017
Model-based clinical dose optimization for phenobarbital in neonates: An illustration of the importance of data sharing and external validationSwantje Völler, Robert B Flint, Leo M Stolk, et al.
Alimentary Pharmacology & Therapeutics|August 27, 2019
Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and childJolien J M Freriksen, Minou van Seyen, Ali Judd, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 7, 2012
Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphismsPhilippe R Mutwa, Quirine Fillekes, Marie Malgaz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 16, 2005
Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapyPieter L A Fraaij, Gwenda Verweel, Annemarie M C van Rossum, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 10, 2004
Nelfinavir plasma concentrations are low during pregnancyJeannine F J B Nellen, Igor Schillevoort, Ferdinand W N M Wit, et al.
Clinical Pharmacology and Therapeutics|January 20, 2022
The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung CancerNikki de Rouw, Merel de Boer, René J Boosman, et al.
Clinical Pharmacokinetics|April 24, 2016
Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and EnzalutamideGuillemette E Benoist, Rianne J Hendriks, Peter F A Mulders, et al.
The Journal of Antimicrobial Chemotherapy|January 1, 2019
Protein binding of rifampicin is not saturated when using high-dose rifampicinCarlijn H C Litjens, Rob E Aarnoutse, Eleonora W J van Ewijk-Beneken Kolmer, et al.
Clinical Pharmacokinetics|January 9, 2021
Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic AnalysisNikki de Rouw, Rene J Boosman, Alwin D R Huitema, et al.
Therapeutic Drug Monitoring|August 15, 2000
Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavirP W Hugen, D M Burger, M de Graaff, et al.
Pageof 113

Showing results (821-830 of 1,123) with videos related to

Sort By:
Pageof 113
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 17, 2017
Model-based clinical dose optimization for phenobarbital in neonates: An illustration of the importance of data sharing and external validationSwantje Völler, Robert B Flint, Leo M Stolk, et al.
Alimentary Pharmacology & Therapeutics|August 27, 2019
Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and childJolien J M Freriksen, Minou van Seyen, Ali Judd, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 7, 2012
Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphismsPhilippe R Mutwa, Quirine Fillekes, Marie Malgaz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 16, 2005
Sustained viral suppression and immune recovery in HIV type 1-infected children after 4 years of highly active antiretroviral therapyPieter L A Fraaij, Gwenda Verweel, Annemarie M C van Rossum, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 10, 2004
Nelfinavir plasma concentrations are low during pregnancyJeannine F J B Nellen, Igor Schillevoort, Ferdinand W N M Wit, et al.
Clinical Pharmacology and Therapeutics|January 20, 2022
The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung CancerNikki de Rouw, Merel de Boer, René J Boosman, et al.
Clinical Pharmacokinetics|April 24, 2016
Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and EnzalutamideGuillemette E Benoist, Rianne J Hendriks, Peter F A Mulders, et al.
The Journal of Antimicrobial Chemotherapy|January 1, 2019
Protein binding of rifampicin is not saturated when using high-dose rifampicinCarlijn H C Litjens, Rob E Aarnoutse, Eleonora W J van Ewijk-Beneken Kolmer, et al.
Clinical Pharmacokinetics|January 9, 2021
Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic AnalysisNikki de Rouw, Rene J Boosman, Alwin D R Huitema, et al.
Therapeutic Drug Monitoring|August 15, 2000
Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavirP W Hugen, D M Burger, M de Graaff, et al.
Pageof 113